SPRO
Spero Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
−0.82%Aug 28, 2026, 21:42 UTC
Spero Therapeutics, Inc. terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., effective August 28, 2026, with no shares sold under the agreement in fiscal years 2024 and 2025.
Aug 28, 2026, 21:42 UTC
Spero Therapeutics, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to sell shares of its common stock at-the-market, with a maximum aggregate offering price of $100 million.
Aug 13, 2026, 02:06 UTC
Spero Therapeutics received FDA approval for Utebzi, a product for immune-mediated diseases.
Source:Aug 12, 2026, 20:01 UTC
Spero Therapeutics announced its operating results for the second quarter ended June 30, 2026.
Jul 14, 2026, 10:02 UTC
Spero Therapeutics announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of KKR.
Source:Jul 14, 2026, 00:00 UTC
Spero Therapeutics signed a cross-exclusive territory license agreement with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc. for CD40L-targeting compounds including SP001 (IBI355).
Jun 17, 2026, 16:36 UTC
The US FDA approved Utebzi (tebipenem pivoxil), an oral antibiotic developed by GSK and Spero Therapeutics, for adults with complicated urinary tract infections in the US.